Subscribe
shutterstock_1572740566_nitpicker
nitpicker / Shutterstock.com
13 April 2021Big PharmaRory O'Neill

Sanofi and C4X in $493m licensing deal

UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million ($493 million), which will see the French pharmaceutical company develop anti-inflammatory therapies.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.
Medtech
PTAB invalidates Sanofi injector patent
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
The uncertain future of antibody claims
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.
Medtech
PTAB invalidates Sanofi injector patent
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
The uncertain future of antibody claims
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.

More on this story

Americas
Fed Circ rejects Sanofi’s bid to resurrect Lantus patents
4 January 2022   The US Court of Appeals for the Federal Circuit has rejected several bids from French pharma giant Sanofi to revive claims in its Lantus SoloStar insulin pen patents.
Medtech
PTAB invalidates Sanofi injector patent
1 April 2021   Mylan Pharmaceuticals has succeeded in getting the Patent Trial and Appeal board (PTAB) to invalidate an injector patent held by French pharmaceutical company Sanofi
Biotechnology
The uncertain future of antibody claims
1 April 2021   Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB